
Gastritis - Pipeline Insight, 2024
Description
Gastritis - Pipeline Insight, 2024
DelveInsight’s, Gastritis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Gastritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastritis: Overview
Gastritis has its basis in histological features of the gastric mucosa. It is not erythema observed during gastroscopy, and there are no specific clinical presentations or symptoms defining it. The current classification of gastritis centers on time course (acute versus chronic), histological features, anatomic distribution, and underlying pathological mechanisms. Acute gastritis will evolve to chronic, if not treated. Helicobacter pylori (H. pylori) is the most common cause of gastritis worldwide.
H.pylori-associated gastritis transmission is via the fecal-oral route. H. pylori possess several virulence factors which facilitate cell adhesion (e.g., BabA/B, sabA, OipA), cell damage and disruption of tight junctions (e.g., Ure A/B), and evasion from the immune response (e.g. LPS). In particular, the cytotoxin-associated gene a (CagA) is considered a potent inducer of inflammation and correlate with gastric cancer development.
The prognosis depends on the cause. For most people who undertake treatment, the symptoms do decrease but recurrences are common. Patients with H.pylori induced gastritis also have a small risk of developing gastric cancer in future.
Treatment regimens differ from antibiotics (in H. pylori gastritis) to vitamin supplementation (in autoimmune metaplastic atrophic gastritis) to immunomodulatory therapy (in autoimmune enteropathy) to dietary modifications (in eosinophilic gastritis).
""Gastritis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastritis pipeline landscape is provided which includes the disease overview and Gastritis treatment guidelines. The assessment part of the report embraces, in depth Gastritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Gastritis. The therapies under development are focused on novel approaches to treat/improve Gastritis.
- In June 2021, Neurogastrx announced that it has entered into an exclusive license agreement with Daewoong Pharmaceutical, for the development and commercialization of fexuprazan, an investigational novel potassium-competitive acid blocker (P-CAB) for the treatment of erosive esophagitis (EE) and other acid-related conditions
Gastritis Emerging Drugs
- Fexuprazan: Daewoong Pharmaceutical
- RHB-102: RedHill Biopharma
Further product details are provided in the report……..
Gastritis: Therapeutic Assessment
This segment of the report provides insights about the Gastritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gastritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastritis drugs.
Gastritis Report Insights
- Gastritis Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastritis drugs?
- How many Gastritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daewoong Pharmaceutical
- RedHill Biopharma
- Add Pharma
- Allakos
- Hanmi Pharmaceutical Company Limited
- GC Pharma
- Addpharma
- Fexuprazan
- RHB-102
- AD-203
- AD-215
- AK-002
- HIP2101
- DWJ-1366
- GC-6101A
- AD 212
- NT-2150
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Gastritis: Overview
- What is Gastritis?
- Types of Gastritis
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Gastritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- HIP2101: Hanmi Pharmaceutical Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- GC-6101A: GC Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Discovery Stage Products
- Comparative Analysis
- AD 215: Addpharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Gastritis Key Companies
- Gastritis Key Products
- Gastritis- Unmet Needs
- Gastritis- Market Drivers and Barriers
- Gastritis- Future Perspectives and Conclusion
- Gastritis Analyst Views
- Gastritis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.